Genmab — Juni 2020
-
** However, the error did not impact the broker's revenue or earnings model assumptions
** CS cuts it target price to DKK 2,235 from DKK 2,300 using the average Biotech and Specialty Pharma EV/NPV premium of 30%
** Following significant stock performance in H1 2020, the broker sees more limited near-term upside
** It still sees ofatumumab sales by partner Novartis NOVN.S as underappreciated
** It expects more modest further catalysts in H2 2020 following the positive AbbVie's ABBV.N oncology pa -
partnership with Genmab and epcoritamab data
-
Community Advice: SQ Formulation of Daratumumab https://www.youtube.com/watch?v=nuL179KaL5U
-
I øvrigt.. pisseflot hjemmeside GEN har fået banket op. Stor cadeau! Synes I alle skal bruge 30 min på at tjekke den ud. Den er moderne, homogen, gennemtænkt modulær, og med mange lækre features. Hele investor-delen. Pipelinen. Og specielt de 4 3-dimensionale logoers dans på forsiden er pænt lavet
-
Så røg den i plus:-)
-
De prøver og prøver de store, men de finder med tiden ud af at de ikke kan knocke the socks of! og derfor må de have den store muldvarp frem.......i mellemtiden er Genmab steget til 60bn$ i salgspris og efter bud må vinderen hive 80bn$ frem og denne episke og næsten sandfærdige historie udløser hvidvin til solnedgangen i aften.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind